November 27, 2019Open Access

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Key Points

Key points are not available for this paper at this time.

Abstract

Among patients with NMOSD, satralizumab added to immunosuppressant treatment led to a lower risk of relapse than placebo but did not differ from placebo in its effect on pain or fatigue. (Funded by Chugai Pharmaceutical; ClinicalTrials.gov number, NCT02028884.).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Yamamura et al. (Wed,) studied this question.

synapsesocial.com/papers/69d7c8fa3b601d7be3ae2ebe https://doi.org/https://doi.org/10.1056/nejmoa1901747

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.2003 · 1,506 citations
2Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization2010 · 350 citations
3IL‐6: Regulator of Treg/Th17 balance2010 · 1,570 citations
4Sensitivity to censored‐at‐random assumption in the analysis of time‐to‐event endpoints2016 · 48 citations
5Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder2016 · 11 citations

Bookmark

View Full Paper